Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C4 TherapeuticsCCCC +2.50%49 OCF Yield % is -16.83 as of Aug. 25, 2026. GuruFocus rates CCCC with a GF Score™ of 49/100 and a GF Value™ of $2.05 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, C4 Therapeutics ranks worse than 65.18% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
C4 Therapeutics OCF Yield % Related Terms
C4 Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for C4 Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, C4 Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C4 Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, C4 Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where C4 Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C4 Therapeutics (CCCC) has a OCF Yield % of -16.83 as of Aug. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on C4 Therapeutics and its competitors. According to the industry distribution chart, C4 Therapeutics ranks #919 out of 1410 companies in the Biotechnology industry, placing it in the top 65.2%.
Is C4 Therapeutics' OCF Yield % too high?
C4 Therapeutics' current OCF Yield % is -16.83. Based on the distribution chart, C4 Therapeutics ranks #919 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, C4 Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C4 Therapeutics' OCF Yield % compare to CMPX and AVIR?
According to the Biotechnology industry distribution chart, C4 Therapeutics ranks #919 out of 1410 companies for OCF Yield %. This places C4 Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on C4 Therapeutics and its competitors. C4 Therapeutics's current OCF Yield % is -16.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C4 Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, C4 Therapeutics (CCCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.05, compared to a current price of $4.12 — trading 100.7% above its estimated fair value. The current OCF Yield % is -16.83. C4 Therapeutics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For C4 Therapeutics (CCCC), the current OCF Yield % is -16.83 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C4 Therapeutics (CCCC) Overvalued in 2026?
Based on GuruFocus' analysis, C4 Therapeutics stock appears to be overvalued.
The current stock price of $4.12 is trading 100.7% above its estimated GF Value™ of $2.05.
GuruFocus considers C4 Therapeutics to be Significantly Overvalued.
Key valuation signals for CCCC:
OCF Yield %: -16.83
GF Value™: $2.05 vs. price of $4.12 (100.7% above fair value)
No single metric tells the full story. See the CCCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
49GF Score
Get the complete analysis for CCCC
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCCC has been successfully added to your 
